IPSC (28) LCTX (29) FATE (40) OCGN (35) ⌘ Pro Terminal →

Cabaletta Bio Inc. (CABA) — RQD Stock Rating Cockpit

$1.59 +4.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cabaletta Bio Inc. (CABA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $268.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CABA)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

37.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE9% OF RANGE

L: $1$1.59H: $4

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CABA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

15/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CABA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CABA)

✓Walkthrough of CABA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CABA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.82%▼ DESCENDING CHANNEL

2026-10-30O $1.55H $1.59L $1.43C $1.59VOL 3.73M

RES: $3.52SUP: $1.27SMA50: $2.30SMA200: $2.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CABA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CABA Butterfly Map → + Track CABA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CABA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CABA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CABA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CABA)

Health Care Rank #575 of 1016 ⚔️ IPSC vs CABA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CABA vs. IPSC, LCTX, FATE, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cabaletta Bio Inc. (CABA) ranks #575 by composite RQD confidence (42/100, grade D-) and #533 by equity capitalization ($268.7M). Within this direct 5-issuer industry benchmark cohort, CABA leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. CABA currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CABA ACTIVE Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	Benchmark Subject
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-caba →
LCTX Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	/lctx-vs-caba →
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-caba →
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-caba →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759138

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cabaletta Bio Inc. (CABA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$167.9M, operating cash flow of -$131.1M, and free cash flow of -$132.3M (-46.3% YoY). On the balance sheet, CABA closed FY2025 with $165.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$167.9M	-$131.1M	-$132.3M	$165.1M	—
FY2024 (FY)	2024-12-31	$0	-$115.9M	-$88.2M	-$90.4M	$185.0M	—
FY2023 (FY)	2023-12-31	$0	-$67.7M	-$53.5M	-$53.5M	—	—

3. CABA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CABA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cabaletta Bio Inc. (NASDAQ: CABA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.59 (+4.28% 1D, market cap $268.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CABA ranks #575 in composite RQD confidence.

How does CABA compare to IPSC and LCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CABA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPSC (Century Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -14.1%, cap $264.4M) and LCTX (Lineage Cell Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M). Among the 5-stock peer group, CABA leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CABA?

Per CABA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759138), Cabaletta Bio Inc. generated $0 in revenue, -$167.9M in net income, and -$132.3M in free cash flow against $165.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CABA trading relative to its 50-day, 200-day, and 52-week technical levels?

CABA last traded at $1.59 (+4.28% on volume of 5,412,148 shares), positioning the stock -30.87% below its 50-day simple moving average ($2.30) and -44.41% below its 200-day simple moving average ($2.86). Across its 52-week range of $1.32 to $4.23, CABA sits at the 9.3% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.39 to $1.79).

CABA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CABA stock right now?

Cabaletta Bio Inc. (CABA) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CABA's 12-month price target and RQD AI Jury consensus?

CABA's 12-month base price target is $1.48 (range $1.15 to $4.44), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CABA RQD Cockpit CABA 12M Forecast CABA Earnings & Move CABA Dividends & DRIP CABA Insiders & 13F CABA Whale Options CABA Profit Sankey CABA News & Why